The Disease Biomarkers section aims to bridge the identification and validation of discovered gene or protein-based, network or dynamic network biomarkers with human diseases, patient phenotypes, or clinical applications, and accelerate the development of human disease-specific biomarkers for the early diagnosis, monitoring, evaluation, and prediction of diseases.
Edited by Xiangdong Wang, the section welcomes research on the development of advanced biotechnologies for biomarker discovery and development, identifying biomarkers associated with the early detection of diseases, monitoring of disease severity and duration as well as patient responses to therapies, prediction of patient outcomes and the evaluation, regulation and ethics of disease biomarkers.
© peterschreiber.media / Getty Images / iStock
Mechanisms underlying sex differences in both susceptibility and response to SARS-CoV-2 infection remain poorly understood. The extent to which such paradoxical sex differences in triggered autoimmunity may exist and persist across the broader clinical spectrum of SARS-CoV-2 infection is unclear.
In this study, researchers sought to comprehensively examine the diversity of antibody responses in male and female health care workers (HCWs) who were exposed to SARS-CoV-2 and self-reported presence or absence of distinct symptoms associated with COVID-19. Results reveal that prior SARS-CoV-2 infection, even in the absence of severe clinical disease, can lead to a broad AAB response that exhibits sex-specific patterns of prevalence and antigen selectivity.
© Zhang et al, 2021
Chimeric antigen receptor T cell (CAR-T cell) therapy is a relatively new, effective, and rapidly evolving therapeutic for adoptive immunotherapies. Although it has achieved remarkable effect in hematological malignancies, there are some problems that remain to be resolved. For example, there are high recurrence rates and poor efficacy in solid tumors.
In this review, researchers describe the metabolic re-editing of T cells and the changes in metabolism during the preparation of CAR-T cells. Furthermore, researchers summarize the latest developments and newest strategies to improve the metabolic adaptability and antitumor activity of CAR-T cells in vitro and in vivo.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreGet to know the Editors behind Journal of Translational Medicine!
The original article was published in Journal of Translational Medicine 2021 19:471
Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection
Check out last month's top 20 most discussed articles from Journal of Translational Medicine!
nadia_buravleva / stock.adobe.com
Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020).
Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine.
The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.
Led by Section Editor Marcello Maggiolini, this exciting new section is dedicated to uncovering pivotal transduction signaling involved in pathophysiological processes toward a translational impact on the discovery of novel targets and therapeutics.
Translational Signaling and System Biology section welcomes articles providing new mechanistic insights on a broad range of fields, drug action through new formulations and delivery methods, novel cellular and animal models, computational and systems biology, and innovative laboratory concepts fostering translational research from the bench to the bedside.
Led by Section Editor Giuseppe Intini, this new section aims to foster new discoveries in the field of Craniofacial and Dental Medicine. It is interested in interested in research that investigates innovative approaches in all craniofacial and dental specialties, including oral medicine and oral pathology.
Translational Craniofacial and Dental Medicine will consider studies regarding therapeutic approaches for treatment of diseases and for tissue regeneration, biomaterials for restorative prosthesis and implantology, diagnostic tools, imaging, and large data analysis. Translational genomics and precision medicine studies that identify novel prognostic markers, tailored interventions, and prophylactic approaches are also welcome.
Led by Section Editor Claire Vanpouille-Box, this new section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity.
Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources, biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, the section welcomes translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome.
Led by Section Editor Gennaro Ciliberto, this exciting section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments.
Emerging Therapeutics is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.
Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.
Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
Speed
60 days to first decision for reviewed manuscripts only
31 days to first decision for all manuscripts
115 days from submission to acceptance
13 days from acceptance to publication
Citation Impact
5.531 - 2-year Impact Factor
5.760 - 5-year Impact Factor
1.244 - Source Normalized Impact per Paper (SNIP)
1.576 - SCImago Journal Rank (SJR)
Usage
2,701,735 Downloads
3,471 mentions